Resolution of hydronephrosis due to massive mesenteric fibromatosis using cyclo-oxygenase 2 inhibitors.
Mesenteric fibromatosis is currently a diagnostic and therapeutic challenge. We report a case of mesenteric fibromatosis in a 29-year-old man with a 2-month history of periumbilical fullness who was discovered to have an abdominal mass with hydronephrosis. To the best of our knowledge, we report the first case of hydronephrosis in a mesenteric fibromatosis with Gardner's syndrome, which was successfully treated with a cyclo-oxygenase 2 inhibitor without surgical removal of the mesenteric fibromatosis. The hydronephrosis and mesenteric fibromatosis improved modestly with long-term celecoxib (200 mg twice daily). Our case also highlights the importance of performing a detailed examination in patients with hydronephrosis.
Ng
Teik-Ying
TY
Department of Surgery, China Medical University Hospital, Taichung, Taiwan.
Yang
Mei-Due
MD
Chen
Yung-Fang
YF
Chang
Chao-Hsiang
CH
D000328:Adult; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005350:Fibroma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D005736:Gardner Syndrome / Q000175:diagnosis / Q000235:genetics; D006801:Humans; D006869:Hydronephrosis / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D007813:Laparotomy; D008096:Lithotripsy; D008297:Male; D008643:Mesentery / Q000473:pathology*; D009403:Nephrostomy, Percutaneous; D010534:Peritoneal Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014514:Ureteral Calculi / Q000209:etiology / Q000628:therapy
D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib